ReviewExperientia supplementum (2012)
Neuroprotective role for galanin in Alzheimer's disease.
Review in Experientia supplementum (2012). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Brain peptides in Alzheimer's disease - pathophysiology and therapeutic advances.Cell and tissue research · 2026Review
- Galanin Receptors in the Central Nervous System: Exploring Ligand Interactions, Signal Transduction, and Potential Clinical Implications.Molecules (Basel, Switzerland) · 2026Review
- Galanin Receptors: G Protein-Dependent Signaling and Beyond.Biomolecules · 2026Review
- Sleep and stress as modifiable drivers of Alzheimer's disease.NPJ dementia · 2026Review
- Systematic characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer's disease.Cell reports · 2024Article
- Secretome Analyses Identify FKBP4 as aInternational journal of molecular sciences · 2024Article
- Article
- Spexin modulates molecular thermogenic profile of adipose tissue and thermoregulatory behaviors in female C57BL/6 mice.Hormones and behavior · 2022Article
- Intranasal Delivery of Galanin 2 and Neuropeptide Y1 Agonists Enhanced Spatial Memory Performance and Neuronal Precursor Cells Proliferation in the Dorsal Hippocampus in Rats.Frontiers in pharmacology · 2022Article
- An assembly of galanin-galanin receptor signaling network.Journal of cell communication and signaling · 2021Article
- Neuropathology of the Brainstem to Mechanistically Understand and to Treat Alzheimer's Disease.Journal of clinical medicine · 2021Review
- Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson's disease model.Behavioural brain research · 2019Article
- Transcriptomic Insights into the Response of the Olfactory Bulb to Selenium Treatment in a Mouse Model of Alzheimer's Disease.International journal of molecular sciences · 2019Article
- Subclinical Lipopolysaccharide fromToxins · 2019Article
- Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease.Trends in neurosciences · 2018Review
- Evolution of Brain Active Gene Promoters in Human Lineage Towards the Increased Plasticity of Gene Regulation.Molecular neurobiology · 2018Article
- Cholinergic profiles in the Goettingen miniature pig (Sus scrofa domesticus) brain.The Journal of comparative neurology · 2017Article
- Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.Brain research · 2016Review
- Differential expression of galanin in the cholinergic basal forebrain of patients with Lewy body disorders.Acta neuropathologica communications · 2015Article
- Hippocampal plasticity during the progression of Alzheimer's disease.Neuroscience · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Galanin (GAL) and GAL receptors (GALR) are overexpressed in degenerating brain regions associated with cognitive decline in Alzheimer's disease (AD). The functional consequences of GAL plasticity in AD are unclear. GAL inhibits cholinergic transmission in the hippocampus and impairs spatial memory in rodent models, suggesting that GAL overexpression exacerbates cognitive impairment in AD. By contrast, gene expression profiling of individual cholinergic basal forebrain (CBF) neurons aspirated from AD tissue revealed that GAL hyperinnervation positively regulates mRNAs that promote CBF neuronal function and survival. GAL also exerts neuroprotective effects in rodent models of neurotoxicity. These data support the growing concept that GAL overexpression preserves CBF neuron function, which may in turn delay the onset of symptoms of AD. Further elucidation of GAL activity in selectively vulnerable brain regions will help gauge the therapeutic potential of GALR ligands in the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.